HK Stock Market Move | JUNSHI BIO (01877) opens more than 11% higher, signs a relevant license agreement with Fosun Pharma for the use of the antibody drug Conbercept.
Junshi Biosciences (01877) opened more than 11% higher, as of the time of writing, it is up 11.11% at HK$18.5, with a turnover of HK$1.6724 million.
JUNSHI BIO (01877) opened more than 11% higher, as of the time of publication, it rose by 11.11% to HKD 18.5, with a turnover of HKD 1.6724 million.
On the news front, JUNSHI BIO announced on June 30, 2026 that Shanghai JUNSHI BIO Medical Technology Co., Ltd. (hereinafter referred to as the "Company") has signed a "License Agreement" with Fosun Pharma, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. The agreement grants Fosun Pharma the rights to develop, register, produce, and commercialize the collaboration product Roche's Secukinumab (JS005, anti-IL-17A monoclonal antibody) in Greater China (including mainland China, Hong Kong, Macau, and Taiwan). According to the agreement, the company will receive a non-refundable upfront payment of RMB 215 million (including taxes) and is eligible to receive up to a maximum of RMB 1.125 billion (including taxes) in development and sales milestone payments, as well as tiered sales royalties on the net sales in Greater China.
Related Articles
HK Stock Market Move | Jl Mag Rare-Earth(06680) rose by over 11%, with the expected net profit for the first half of the year to increase by 50.84% year-on-year.
Debt restructuring enters deep water area: restructuring real estate companies have started to optimize plans.
HK Stock Market Move | VISEN PHARMA-B(02561) rose more than 15% in early trading. The company has recently reached a project collaboration with Meghealth to explore new models of diverse payments.
HK Stock Market Move | Jl Mag Rare-Earth(06680) rose by over 11%, with the expected net profit for the first half of the year to increase by 50.84% year-on-year.
Debt restructuring enters deep water area: restructuring real estate companies have started to optimize plans.
HK Stock Market Move | VISEN PHARMA-B(02561) rose more than 15% in early trading. The company has recently reached a project collaboration with Meghealth to explore new models of diverse payments.
RECOMMEND
